SAN CARLOS, Calif., April 2, 2026
Glycomine, Inc. has announced the successful completion of patient enrollment in its global Phase 2b POLAR clinical trial, evaluating GLM101, a novel liposomal mannose-1-phosphate substrate replacement therapy, for the treatment of phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG). This milestone represents a critical step forward in addressing a rare, life-threatening genetic disorder with no approved therapies, as the study advances toward topline data expected in the fourth quarter of 2026, potentially shaping the future of treatment in rare metabolic diseases.
Global Phase 2b Study Targets Ataxia Improvement
The POLAR study is a randomized, double-blind, placebo-controlled trial that has enrolled 43 pediatric and adult patients aged 4 to 47 years across 15 clinical sites in the United States, United Kingdom, and Europe, highlighting the global collaboration required to study ultra-rare diseases. The primary endpoint focuses on improvement in ataxia, a key neurological symptom affecting more than 90% of PMM2-CDG patients, measured using the International Cooperative Ataxia Rating Scale (ICARS) at 24 weeks.
Secondary endpoints include functional and clinical assessments such as the Scale for the Assessment and Rating of Ataxia (SARA), Neuromuscular Gross Motor Outcomes (GRO), and global impression scores, providing a comprehensive evaluation of treatment impact. The trial builds on positive Phase 2a data, where GLM101 demonstrated meaningful improvements in neurological symptoms along with a favorable safety profile, reinforcing its potential as a disease-modifying therapy.
Triple-Combination Mechanism Targets Key Hair Loss Pathways
Advertisement
TH07 is a novel topical formulation combining three pharmacologically active agents—minoxidil, finasteride, and latanoprost—each targeting distinct biological pathways involved in hair loss. This multi-targeted therapeutic approach is designed to address the complex pathophysiology of androgenic alopecia by stimulating hair follicle activity, reducing androgen-mediated follicle miniaturization, and prolonging hair growth cycles. Unlike single-agent therapies, TH07 aims to deliver enhanced clinical efficacy through synergistic action, potentially improving patient outcomes.
Earlier studies indicated that over 80% of participants experienced moderate to significant hair regrowth, supporting continued development into Phase III. The combination of well-characterized active ingredients with a novel delivery system underscores its potential as a next-generation dermatological therapy.
Innovative Mechanism Targets Root Cause of Disease
GLM101 is designed as a substrate replacement therapy that delivers mannose-1-phosphate via a liposomal formulation, addressing the underlying biochemical deficiency in PMM2-CDG. The disorder is caused by reduced activity of the phosphomannomutase 2 enzyme, leading to impaired N-glycosylation, a critical cellular process affecting multiple organ systems. By restoring glycosylation pathways in both the central nervous system and peripheral tissues, GLM101 aims to improve neurological function and systemic disease manifestations.
Administered as a weekly intravenous infusion, the therapy is engineered to achieve broad tissue distribution, overcoming limitations seen in earlier therapeutic approaches. The program has already received Orphan Drug Designation in both the U.S. and EU, along with Rare Pediatric Disease and Fast Track designations, underscoring its regulatory priority and potential clinical significance.
Addressing a Severe Rare Disease with High Unmet Need
PMM2-CDG is the most common congenital disorder of glycosylation, with an estimated prevalence of 1 in 30,000 to 40,000 individuals, affecting up to 50,000 patients worldwide. The disease is characterized by multisystem involvement, including severe neurological impairment, developmental delays, motor dysfunction, and life-threatening complications. Ataxia remains a central and debilitating feature, significantly impacting patient mobility and quality of life.
Despite its severity, there are currently no approved treatment options, leaving patients reliant on supportive care בלבד. The advancement of GLM101 into late-stage clinical development offers a potential first-in-class therapeutic option that directly targets the root metabolic defect, rather than only alleviating symptoms. Glycomine’s continued focus on rare genetic diseases reflects a broader industry shift toward precision medicine and targeted therapies for underserved patient populations.
With enrollment now complete and topline results anticipated in late 2026, the POLAR study positions GLM101 as a promising candidate in the rare disease pipeline, with the potential to deliver clinically meaningful improvements in neurological function and overall disease burden, while advancing the field of substrate replacement therapies in genetic metabolic disorders.
Source: Glycomine, Inc press release
